Olanzapine (Zyprexa)

Small molecule

Also known as LY170053

Approvedregulatory verdict

Evidence outlook

Approved: Schizophrenia, Bipolar Disorder

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also approved (1)
EU
  • Coated tablets Adults Olanzapine is indicated for the treatment of schizophrenia. Olanzapine is effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response. Olanzapine is indicated for the treatment of moderate to severe manic episode. In patients whose manic episode has responded to olanzapine treatment, olanzapine is indicated for the prevention of recurrence in patients with bipolar disorder. Injection Adults Zyprexa powder for solution for injection is indicated for the rapid control of agitation and disturbed...
Product first approved 1996EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (79)
Bipolar Disorder
NCT01977300 · University of British Columbia
2003-01 – 2011-08 · Bipolar I Disorder
What this study did
NCT00618748 · Eli Lilly and Company
2008-02 – 2010-09 · Bipolar I Disorder
What this study did
NCT00510146 · Eli Lilly and Company
2007-08 – 2010-07 · Depression, Bipolar
What this study did
NCT00266630 · Eli Lilly and Company
2005-11 – 2009-05 · Manic or Mixed Episode Associated With Bipolar I Disorder
What this study did
NCT00259272 · Eli Lilly and Company
2005-11 – 2008-05 · Bipolar Disorder I or II
What this study did
NCT00159744 · Organon and Co
2004-11-30 – 2006-04-29 · Bipolar Disorder
What this study did
NCT00113594 · Eli Lilly and Company
2005-06 – 2006-03 · Schizophrenia, Bipolar Disorder
What this study did
NCT00194064 · University Hospitals Cleveland Medical Center
2002-07 – 2006-02 · Bipolar Disorder
What this study did
NCT00485680 · Eli Lilly and Company
2003-12 – 2005-06 · Bipolar Disorder
What this study did
Schizophrenia
NCT05669742 · Tanta University
2023-05-25 – 2026-06-20 · Sodium-glucose Transport Protein Two Inhibitor (SGLT2),Metabolic Deficits Caused by Antipsychotics
What this study did
NCT06649214 · Qilu Pharmaceutical Co., Ltd.
2024-11 – 2026-05 · Schizophrenia
What this study did
NCT03230864 · H. Lundbeck A/S
2017-07-20 – 2019-02-05 · Treatment-resistant Schizophrenia
What this study did
NCT02717195 · H. Lundbeck A/S
2016-04 – 2018-10-08 · Schizophrenia
What this study did
NCT00440843 · VA Connecticut Healthcare System
2007-02 – 2012-06 · Schizophrenia, Schizoaffective Disorder
What this study did
NCT00088465 · Eli Lilly and Company
2004-08 – 2010-12 · Schizophrenic Disorders, Schizoaffective Disorder
What this study did
NCT00320489 · Eli Lilly and Company
2006-04 – 2009-09 · Schizophrenia
What this study did
NCT00797277 · National Taiwan University Hospital
2006-07 – 2009-06 · Schizophrenia, Schizoaffective Disorder, Agitation
What this study did
NCT00401973 · Eli Lilly and Company
2006-11 – 2008-09 · Schizophrenia, Schizoaffective Disorders
What this study did
NCT00347425 · Solvay Pharmaceuticals
2006-12 – 2008-02 · Schizophrenia and Schizoaffective Disorder
What this study did
NCT00350467 · Xian-Janssen Pharmaceutical Ltd.
2006-06 – 2007-09 · Acute Schizophrenia
What this study did
NCT00380224 · Wyeth is now a wholly owned subsidiary of Pfizer
2006-07 – 2007-09 · Schizophrenia
What this study did
NCT00088491 · Eli Lilly and Company
2004-06 – 2006-10 · Schizophrenic Disorders
What this study did
NCT00211562 · Augusta University
2005-10 – 2006-01 · Schizophrenia
What this study did
NCT00145444 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2003-03 – 2005-11 · Schizophrenia, Psychotic Disorders
What this study did
NCT00051298 · Eli Lilly and Company
2002-11 – 2005-04 · Schizophrenia
What this study did
NCT00034892 · AstraZeneca
2002-03 – 2005-03 · Schizophrenia, Psychotic Disorders, Mental Health, Mental Disorders
What this study did
NCT00485901 · Eli Lilly and Company
2004-07 – 2005-01 · Schizophrenia
What this study did
Other / comorbidity
NCT06338683 · Qinghai Red Cross Hospital
2024-03-20 – 2028-03-20 · Advanced Cancer, Olanzapine, Progression Free Survival
What this study did
NCT07208305 · Affiliated Hospital of Qinghai University
2026-02-03 – 2027-12-30 · Nausea, Vomiting
What this study did
NCT05895838 · Christian Hassager
2023-06-16 – 2027-12 · Out-Of-Hospital Cardiac Arrest, Post-Cardiac Arrest Syndrome
What this study did
NCT06200181 · M.D. Anderson Cancer Center
2024-04-02 – 2027-11-01 · Misuse, Opioid
What this study did
NCT06588413 · Augusta University
2024-09-17 – 2027-10 · Multiple Myeloma, Autologous Stem Cell Transplantation
What this study did
NCT07413809 · The Affiliated People's Hospital of Ningbo University
2025-10-31 – 2027-09 · Multiple Myeloma
What this study did
NCT06500234 · Qingdao Central Hospital
2024-06-01 – 2027-05-31 · Nutrition Disorders, Immunotherapy, Cancer, Survival, Prosthesis
What this study did
NCT07633236 · Blokhin's Russian Cancer Research Center
2025-03-28 – 2027-05-31 · Oncology Patients Receiving Chemotherapy, Cachexia-Anorexia Syndrome, Oncology
What this study did
NCT04939090 · Alliance for Clinical Trials in Oncology
2022-01-03 – 2026-12-31 · Advanced Malignant Solid Neoplasm, Anorexia, Hematopoietic and Lymphoid Cell Neoplasm
What this study did
NCT07035821 · Shanghai Children's Medical Center
2025-07-01 – 2026-07-30 · Breakthrough Chemotherapy-Induced Vomiting (CIV) in Pediatric Patients, Pediatric Cancer
What this study did
NCT06850454 · Mahidol University
2025-01-10 – 2026-01-31 · Chemotherapy Induced Nausea and Vomiting
What this study did
NCT06517199 · Mahidol University
2024-01-22 – 2026-01-21 · Anorexia, Cachexia
What this study did
NCT04833023 · Tan Tock Seng Hospital
2022-05-18 – 2025-09-25 · Haloperidol, Advanced Cancer, Hyperactive Delirium, Olanzapine, End-stage Organ Disease
What this study did
NCT06331520 · Fudan University
2024-05-01 – 2025-08-30 · Chemotherapy-induced Nausea and Vomiting, Highly Emetogenic Chemotherapy
What this study did
NCT05403580 · Mayo Clinic
2022-06-03 – 2024-12 · Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm
What this study did
NCT05346731 · Federal Research Institute of Pediatric Hematology, Oncology and Immunology
2022-04-01 – 2024-08 · Chemotherapy-induced Nausea and Vomiting
What this study did
NCT05803642 · Qilu Pharmaceutical Co., Ltd.
2023-03-28 – 2024-07-02 · Acute Agitation
What this study did
NCT05805800 · Xingchen Peng
2023-04-15 – 2024-05-15 · Chemotherapy-induced Nausea and Vomiting
What this study did
NCT03367572 · University of Rochester NCORP Research Base
2018-04-19 – 2024-04-13 · Breast Carcinoma
What this study did
NCT05244577 · Shi Yanxia
2022-01-18 – 2024-03-31 · Olanzapine, CINV, Testicular Cancer by AJCC V6 and V7 Stage, Cisplatin
What this study did
NCT04503668 · University of Michigan Rogel Cancer Center
2020-12-28 – 2024-03-11 · Gynecologic Cancer
What this study did
Phase 2/3 (7)
Other / comorbidity
NCT06175273 · Corey Hawes
2024-01-31 – 2025-08-04 · Pediatric Cancer, Nutrition Related Cancer, Nutrition Aspect of Cancer, Muscle Loss, Malnutrition, Child
What this study did
NCT03631004 · Instituto do Cancer do Estado de São Paulo
2018-10-01 – 2021-02-10 · Postoperative Nausea, Postoperative Nausea and Vomiting
What this study did
NCT03137121 · University of Alabama at Birmingham
2017-07-12 – 2020-09-15 · Advanced Cancer
What this study did
NCT04181385 · University Health Network, Toronto
2019-01-01 – 2020-06-01 · Healthy
What this study did
NCT00876772 · Charite University, Berlin, Germany
2011-03 – 2012-07 · Amyotrophic Lateral Sclerosis (ALS)
What this study did
NCT00183404 · Drexel University
2004-09 – 2011-10 · Autism
What this study did
NCT00910780 · Washington University School of Medicine
2009-11 – 2009-11 · Diabetes
What this study did
Phase 2 (38)
Schizophrenia
NCT07152184 · University Hospital, Strasbourg, France
2026-10-01 – 2032-02-01 · Patient With Schizophrenia Spectrum Disorder, NLM Classification WM 203, Psychology:Schizophrenic Psychology, Schizophrenia Spectrum and Other Psychotic Disorders
What this study did
NCT06821945 · Boryung Pharmaceutical Co., Ltd
2025-05-30 – 2027-05 · Schizophrenia
What this study did
NCT04518319 · Shanghai Mental Health Center
2020-10-01 – 2024-11 · Schizophrenia
What this study did
NCT02161718 · Alkermes, Inc.
2014-05 – 2017-02-01 · Schizophrenia, Alcohol Use Disorder
What this study did
NCT02462473 · Janssen Research & Development, LLC
2015-05 – 2016-01 · Schizophrenia, Schizoaffective Disorder
What this study did
NCT00686998 · AstraZeneca
2008-05 – 2009-03 · Schizophrenia
What this study did
NCT00734435 · Orexigen Therapeutics, Inc
2008-09 – 2008-12 · Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
What this study did
NCT00259870 · GlaxoSmithKline
2005-09 – 2007-08 · Schizophrenia
What this study did
NCT00316238 · Eli Lilly and Company
2006-04 – 2007-05 · Schizophrenia
What this study did
NCT00265551 · Wyeth is now a wholly owned subsidiary of Pfizer
2006-01 – 2007-01 · Schizophrenia
What this study did
NCT00073164 · Abbott
started 2003-07 · Schizophrenia
What this study did
Other / comorbidity
NCT06995508 · Roswell Park Cancer Institute
2025-12-24 – 2031-11-15 · Cancer-Associated Anorexia, Head and Neck Squamous Cell Carcinoma, Neck Squamous Cell Carcinoma of Unknown Primary
What this study did
NCT07581405 · University of Illinois Chicago
2026-11-03 – 2030-11 · Gastric Adenocarcinoma, Gastric Cancer
What this study did
NCT07722806 · Kantonsspital Winterthur KSW
2026-08 – 2028-12 · Cancer, Advanced Solid Tumors, Malnutrition
What this study did
NCT07455955 · Chinese University of Hong Kong
2026-03-31 – 2028-07-03 · Breast Cancer
What this study did
NCT05705492 · OHSU Knight Cancer Institute
2024-07-17 – 2027-06-30 · Advanced Malignant Solid Neoplasm, Advanced Biliary Tract Carcinoma, Advanced Esophageal Carcinoma, Metastatic Esophageal Carcinoma, Locally Advanced Colorectal Carcinoma, Locally Advanced Esophageal Carcinoma, Locally Advanced Gastric Carcinoma, Metastatic Colorectal Carcinoma (mCRC), Advanced Lung Carcinoma, Locally Advanced Hepatocellular Carcinoma
What this study did
NCT06554613 · Second Affiliated Hospital of Nanchang University
2024-07-02 – 2027-05-31 · Non-Small Cell Lung Cancer
What this study did
NCT05170919 · Englewood Hospital and Medical Center
2022-01-20 – 2026-12 · Anorexia Nervosa with Significantly Low Body Weight
What this study did
NCT03118986 · The Hospital for Sick Children
2017-08-10 – 2026-06-12 · Vomiting in Infants and/or Children, Nausea, Hematopoietic System--Cancer, Oncology
What this study did
NCT05676294 · Yale University
2023-06-26 – 2025-12-06 · Postoperative Nausea and Vomiting
What this study did
NCT04750395 · HCA Hospice Care
2021-09-01 – 2024-05 · Delirium, Terminal Illness
What this study did
NCT05202275 · Chinese Academy of Medical Sciences
2020-12-01 – 2023-09 · Nausea, Vomiting, Head and Neck Squamous Cell Carcinoma, Radiotherapy Side Effect
What this study did
NCT05179772 · University of Pennsylvania
2022-07-28 – 2023-01-30 · Opioid Use Disorder
What this study did
NCT03960151 · Costantine Albany
2018-05 – 2022-03 · Germ Cell Tumor
What this study did
NCT04669132 · Instituto Brasileiro de Controle do Cancer
2020-12-17 – 2022-01-17 · Nausea Post Chemotherapy
What this study did
NCT03679182 · Khon Kaen University
2018-09-01 – 2021-09 · Nausea, Vomiting, End Stage Cancer
What this study did
NCT03575637 · Peking University
2018-07 – 2021-06 · Gastric Cancer
What this study did
NCT02755116 · Jaime B Hyman
2016-04 – 2019-09-05 · Postoperative Nausea and Vomiting
What this study did
NCT03478605 · Blokhin's Russian Cancer Research Center
2018-05-25 – 2019-06-01 · Emesis, Vomiting, Nausea Post Chemotherapy, Nausea, Chemotherapy-induced Nausea and Vomiting
What this study did
NCT02400866 · Korean South West Oncology Group
2015-05 – 2017-04 · Cancer
What this study did
NCT02129478 · The Hospital for Sick Children
2014-03 – 2016-01 · Chemotherapy-induced Nausea and Vomiting
What this study did
NCT02290470 · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
2014-04 – 2015-11 · Nausea, Vomiting
What this study did
NCT02097823 · Indiana University
2014-02 – 2015-03 · Chemotherapy Induced Nausea and Vomiting
What this study did
NCT01148264 · Karin Jordan
2010-07 – 2014-10 · Emesis
What this study did
NCT00692185 · New York State Psychiatric Institute
2005-10 – 2010-09 · Eating Disorders
What this study did
NCT00678457 · University of Virginia
2007-01 – 2008-05 · Alcohol Dependence
What this study did
NCT00260962 · Ottawa Hospital Research Institute
2000-09 – 2006-09 · Anorexia Nervosa
What this study did
NCT00057408 · FDA Office of Orphan Products Development
2003-05 – 2005-09 · Autistic Disorder
What this study did
Phase 1/2 (7)
Schizophrenia
NCT02650102 · Shanxi Medical University
2013-01 – 2016-12 · Schizophrenia
What this study did
NCT00446992 · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
2006-04 – 2010-03 · Schizophrenia
What this study did
NCT00089869 · Eli Lilly and Company
— · Schizophrenia
What this study did
NCT00485810 · Eli Lilly and Company
2004-06 – 2004-11 · Schizophrenia
What this study did
Other / comorbidity
NCT05814640 · First Affiliated Hospital of Chongqing Medical University
2023-02-20 – 2027-07-01 · Depression, Sequestra
What this study did
NCT04718727 · Amani Hassan Abdel-Wahab
2021-03-15 – 2023-02-01 · Postoperative Nausea
What this study did
NCT01282632 · Sunnybrook Health Sciences Centre
2002-08 – 2004-03 · Subjects Had Unipolar, Non-psychotic Major Depression
What this study did
Phase 1 (31)
Bipolar Disorder
NCT02087579 · Janssen Research & Development, LLC
2014-02 – 2014-12 · Psychotic Disorders, Schizophrenia, Bipolar Disorder, Depressive Disorder
What this study did
Schizophrenia
NCT03781115 · University of Arizona
2017-11-20 – 2027-02-10 · Schizophrenia
What this study did
NCT06319170 · Teva Branded Pharmaceutical Products R&D LLC
2024-03-28 – 2025-01-20 · Schizophrenia, Schizoaffective Disorder
What this study did
NCT03790085 · Tianjin Medical University General Hospital
2018-09-01 – 2020-12-31 · Schizophrenia, Major Depressive Disorder, Anxiety Disorders
What this study did
NCT02051387 · Central Institute of Mental Health, Mannheim
2013-01 – 2017-08 · Schizophrenia
What this study did
NCT00287352 · University of North Carolina, Chapel Hill
2005-05 – 2009-09 · Psychotic Disorder, Schizophreniform Disorder, Schizophrenia, Schizoaffective Disorder, Mood Disorders With Psychotic Features
What this study did
NCT03730857 · Calo Psychiatric Center
2008-01 – 2008-12 · Schizophrenia
What this study did
NCT00150215 · Pfizer
2005-07 – 2005-10 · Schizophrenia
What this study did
Other / comorbidity
NCT07662200 · Ottawa Hospital Research Institute
2026-08 – 2028-08 · Germ Cell Cancer
What this study did
NCT04216329 · National Cancer Institute (NCI)
2020-07-07 – 2026-07-09 · Gliosarcoma, Newly Diagnosed, Glioblastoma
What this study did
NCT03741478 · Centre for Addiction and Mental Health
2019-10-22 – 2026-06-01 · Healthy Controls
What this study did
NCT05964647 · University Hospital, Basel, Switzerland
2024-02-01 – 2025-06-30 · Healthy
What this study did
NCT07190482 · University of Sao Paulo
2023-10-01 – 2025-01-20 · Tinnitus, Tinnitus, Subjective
What this study did
NCT06600477 · Neurelis, Inc.
2023-10-16 – 2023-11-01 · Healthy
What this study did
NCT03030417 · National Cancer Institute (NCI)
2017-02-27 – 2023-10-12 · Solid Tumors, Lymphoma
What this study did
NCT02708394 · Wayne State University
2017-02-01 – 2023-10-01 · Adverse Effect of Other Antipsychotics and Neuroleptics, Insulin Resistance
What this study did
NCT05857566 · Response Pharmaceuticals
2023-05-16 – 2023-09-13 · Drug-induced Weight Gain
What this study did
NCT03877562 · Corcept Therapeutics
2019-04-01 – 2020-03-25 · Antipsychotic-induced Weight Gain
What this study did
NCT02634463 · Janssen Research & Development, LLC
2015-11-09 – 2016-11-09 · Immunoassay, Antipsychotic
What this study did
NCT02447835 · Michael Rickels
2012-08 – 2014-12 · Normal Non-fluency
What this study did
NCT00489593 · M.D. Anderson Cancer Center
2006-10 – 2013-12 · Advanced Cancer, Weight Loss
What this study did
NCT01607762 · Janssen Research & Development, LLC
2012-02 – 2012-10 · Healthy
What this study did
NCT01503398 · Dr. Reddy's Laboratories Limited
2011-08 – 2011-09 · Fasting
What this study did
NCT01503424 · Dr. Reddy's Laboratories Limited
2011-08 – 2011-09 · Fed
What this study did
NCT00977301 · Radboud University Medical Center
2009-11 – 2010-08 · HIV Infections
What this study did
NCT01996501 · Torrent Pharmaceuticals Limited
est. completion 2009-01 · Healthy
What this study did
NCT01996488 · Torrent Pharmaceuticals Limited
est. completion 2009-01 · Healthy
What this study did
NCT01503437 · Dr. Reddy's Laboratories Limited
2006-11 – 2006-12 · Fasting
What this study did
NCT01503450 · Dr. Reddy's Laboratories Limited
2006-11 – 2006-12 · Fed
What this study did
NCT00255879 · University of California, San Diego
1999-01 – 2004-08 · Dyskinesia, Drug-Induced
What this study did
Phase 4 (102)
Bipolar Disorder
NCT02287259 · Tadashi Hasegawa
2014-11 – 2019-03-31 · Bipolar Disorder
What this study did
NCT01893229 · Guiyun Xu
2013-09 – 2015-12 · Bipolar Disorder
What this study did
NCT00202293 · Melbourne Health
2001-10-01 – 2015-11-01 · Bipolar Disorder, Schizoaffective Disorder
What this study did
NCT00982020 · Eli Lilly and Company
2009-09 – 2013-05 · Bipolar I Disorder, Schizophrenia
What this study did
NCT01864551 · Tri-Service General Hospital (TSGH)
2008-08 – 2012-09 · Bipolar Disorder
What this study did
NCT00205699 · Washington University School of Medicine
2006-04 – 2011-07 · Aggression, Attention Deficit-Hyperactivity, Oppositional Defiant Disorder, Pervasive Development Disorders, Bipolar Disorder
What this study did
NCT01303601 · China Medical University, China
2009-01 – 2010-10 · Bipolar Disorder, Depression, Bipolar
What this study did
NCT00186017 · Stanford University
2005-07 – 2010-06 · Bipolar Disorder
What this study did
NCT00520507 · Queen's University
2007-10 – 2009-05 · Bipolar Disorder, Depression, Depressive Disorder
What this study did
NCT00402324 · Eli Lilly and Company
2006-12 – 2008-02 · Bipolar I Disorder
What this study did
NCT00303602 · Eli Lilly and Company
2006-03 – 2007-12 · Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
What this study did
NCT00094549 · Eli Lilly and Company
2004-10 – 2006-12 · Bipolar Disorder
What this study did
NCT00048802 · Northwell Health
2002-08 – 2006-08 · Bipolar Disorder
What this study did
NCT00190892 · Eli Lilly and Company
2004-09 – 2006-06 · Bipolar Disorder
What this study did
NCT00191997 · Eli Lilly and Company
2004-10 – 2006-03 · Bipolar Disorder
What this study did
NCT00221481 · Mayo Clinic
est. completion 2006-03 · Bipolar Disorder
What this study did
NCT00050206 · Eli Lilly and Company
2002-11 – 2005-05 · Bipolar Disorder
What this study did
NCT00767715 · Eli Lilly and Company
2004-10 – 2005-04 · Bipolar Disorder
What this study did
NCT00485771 · Eli Lilly and Company
2003-11 – 2005-01 · Bipolar Disorder
What this study did
NCT00181935 · Massachusetts General Hospital
2001-03 – 2004-07 · Bipolar Disorder, Mania
What this study did
NCT00182013 · Massachusetts General Hospital
2001-06 – 2004-02 · Bipolar Spectrum Disorder
What this study did
NCT00177567 · University of Pittsburgh
2001-07 – 2004-01 · Bipolar Disorder
What this study did
NCT00034580 · Eli Lilly and Company
2001-08 – 2002-08 · Bipolar Disorder
What this study did
Schizophrenia
NCT04478838 · Centre for Addiction and Mental Health
2022-06-06 – 2028-09-30 · Schizophrenia and Related Disorders, Drug Administration Schedule, Drug Therapy, Antipsychotic Agents
What this study did
NCT03568500 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2018-05-21 – 2019-09-06 · Schizophrenia, Schizoaffective Disorder, First Episode Psychosis
What this study did
NCT01609153 · Heinrich-Heine University, Duesseldorf
2012-06 – 2019-04 · Schizophrenia, Schizoaffective Disorder
What this study did
NCT02435654 · Kunming Medical University
2015-08 – 2018-12 · Early-onset Schizophrenia
What this study did
NCT01446328 · Haukeland University Hospital
2011-10 – 2017-12 · Schizophrenia, Psychotic Disorders
What this study did
NCT01185743 · Medical University of Vienna
2010-07 – 2017-01-01 · Schizophrenia, Diabetes
What this study did
NCT02307396 · Technical University of Munich
2015-02-01 – 2016-06-22 · Schizophrenia, Schizophrenia and Disorders With Psychotic Features, Schizoaffective Disorders
What this study did
NCT02704962 · Kaohsiung Kai-Suan Psychiatric Hospital
2012-01 – 2016-02 · Schizophrenia
What this study did
NCT02593734 · University of Ghana Medical School
2013-07 – 2015-07 · Schizophrenia, Mood Disorders,, Anxiety Disorder
What this study did
NCT01164059 · University of Bremen
2010-02 – 2014-03 · Schizophrenia
What this study did
NCT01052389 · Mario Negri Institute for Pharmacological Research
2007-07 – 2013-06 · Schizophrenia
What this study did
NCT02137993 · HK inno.N Corporation
2012-03 – 2013-05 · Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder
What this study did
NCT00245206 · Veterans Medical Research Foundation
2005-08 – 2010-10 · Schizophrenia, Alzheimer's Disease, Dementia
What this study did
NCT00918021 · Niuvanniemi Hospital
2009-06 – 2010-07 · Schizophrenia, Schizoaffective Disorder
What this study did
NCT00672464 · Duke University
2008-04 – 2010-02 · Schizophrenia, Schizoaffective Disorder
What this study did
NCT00802100 · National Institute of Mental Health (NIMH)
2008-12 – 2009-10 · Schizophrenia
What this study did
NCT01149577 · Central Institute of Psychiatry, Ranchi, India
2007-08 – 2009-04 · Schizophrenia, Sleep
What this study did
NCT00044655 · Icahn School of Medicine at Mount Sinai
2001-07 – 2009-03 · Schizophrenia
What this study did
NCT00190749 · Eli Lilly and Company
2003-10 – 2008-06 · Schizophrenia, Schizoaffective Disorder
What this study did
NCT00001656 · National Institute of Mental Health (NIMH)
1997-06 – 2008-06 · Childhood Schizophrenia, Psychotic Disorder, Schizophrenia
What this study did
NCT00290121 · Université de Montréal
2006-09 – 2008-06 · Schizophrenia
What this study did
NCT00176436 · University of Maryland, Baltimore
2004-02 – 2008-03 · Schizophrenia
What this study did
NCT00337662 · Eli Lilly and Company
2006-05 – 2007-12 · Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
What this study did
NCT00287820 · Nathan Kline Institute for Psychiatric Research
2004-02 – 2007-09 · Schizophrenia, Diabetes, Metabolic Syndrome, Hyperglycemia
What this study did
NCT00324051 · Eli Lilly and Company
2006-05 – 2007-09 · Schizophrenia
What this study did
Early phase / not applicable (50)
Bipolar Disorder
NCT00512070 · Seattle Institute for Biomedical and Clinical Research
2007-07 – 2024-12 · Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Obesity, Metabolic Syndrome
What this study did
NCT00934908 · Medical University of South Carolina
2009-03 – 2009-03 · Bipolar Disorder, Schizophrenia
What this study did
NCT00179062 · Vanderbilt University
2000-02 – 2007-06 · Schizophrenia, Schizoaffective Disorder, Depressive Disorder, Major, Bipolar Disorder
What this study did
NCT00183612 · Massachusetts General Hospital
2000-05 – 2007-04 · Bipolar Disorder, Psychotic Disorders
What this study did
Schizophrenia
NCT04076371 · Beijing HuiLongGuan Hospital
2012-01 – 2018-12 · Schizophrenia
What this study did
NCT02007928 · Centre Hospitalier Universitaire de Nice
2013-04 – 2017-07 · Dissociative Disorders, Schizophrenia
What this study did
NCT02850445 · Guangzhou Psychiatric Hospital
2012-01 – 2016-12 · Schizophrenia
What this study did
NCT00716755 · Centre for Addiction and Mental Health
2009-10 – 2015-08 · Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Delusional Disorder, Psychotic Disorder
What this study did
NCT01029769 · Technical University of Munich
2009-12 – 2015-03 · Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
What this study did
NCT01389908 · Shalvata Mental Health Center
2011-06 – 2014-07 · Schizophrenia, Schizoaffective Disorders
What this study did
NCT00885690 · University of Aarhus
2009-04 – 2012-11 · Schizophrenia
What this study did
NCT01057849 · Peking University
2008-09 – 2011-03 · Schizophrenia
What this study did
NCT00515723 · Washington University School of Medicine
2001-09 – 2008-12 · Schizophrenia, Schizoaffective Disorder, Type 2 Diabetes Mellitus, Hyperglycemia
What this study did
NCT00225498 · Northwell Health
2002-06 – 2008-10 · Schizophrenia
What this study did
NCT01234454 · University of North Carolina, Chapel Hill
2002-01 – 2007-12 · Schizophrenia
What this study did
NCT00169702 · Heinrich-Heine University, Duesseldorf
2003-06 – 2007-07 · Schizophrenia
What this study did
NCT00534183 · Central Institute of Psychiatry, Ranchi, India
2006-06 – 2006-12 · Metabolic Syndrome, Diabetes, Obesity
What this study did
NCT00006195 · National Center for Research Resources (NCRR)
— · Schizophrenia
What this study did
NCT01160991 · Central Institute of Mental Health, Mannheim
2004-05 – 2006-10 · Schizophrenia, Diabetes, Insulin Resistance
What this study did
NCT00205725 · Washington University School of Medicine
2000-11 – 2006-10 · Schizophrenia, Type 2 Diabetes Mellitus
What this study did
NCT00205738 · Washington University School of Medicine
2000-07 – 2006-10 · Schizophrenia, Type 2 Diabetes Mellitus
What this study did
NCT00222495 · University of Minnesota
2002-08 – 2006-08 · Psychotic Disorders, Schizophrenia, Schizophreniform Disorders, Schizoaffective Disorders
What this study did
NCT01123408 · Nathan Kline Institute for Psychiatric Research
1999-06 – 2004-07 · Schizophrenia
What this study did
NCT00179231 · Vanderbilt University
2000-05 – 2004-02 · Schizophrenia, Schizoaffective Disorder
What this study did
Other / comorbidity
NCT07442890 · Henan Cancer Hospital
2026-04-30 – 2028-06-30 · Lung Cancer
What this study did
NCT05635227 · Copenhagen University Hospital, Rigshospitalet
2022-11-10 – 2028-02 · Coronary Artery Disease, Aortic Valve Disease
What this study did
NCT07743827 · Alexandria University
2026-05-10 – 2027-10-15 · Olanzapine, Breast Cancer, Dexamethasone
What this study did
NCT06251635 · Centre for Addiction and Mental Health
2024-06-03 – 2026-12-31 · Insulin Resistance, Menstrual Cycle, Type 2 Diabetes, Antipsychotics
What this study did
NCT06288854 · Department of Medical Services Ministry of Public Health of Thailand
2024-04-03 – 2025-06-30 · Weight Gain
What this study did
NCT06200584 · Dr Rabia Arshad
2021-01-01 – 2021-06-10 · Antipsychotics and Neuroleptics Toxicity
What this study did
NCT01625923 · University of Michigan
2013-01 – 2019-06 · Idiopathic Gastroparesis
What this study did
NCT02970643 · Hee Jun Kim
2016-07 – 2017-12 · Chemotherapy-induced Nausea and Vomiting
What this study did
NCT02643355 · Hennepin Healthcare Research Institute
2015-11 – 2017-06-21 · Substance Withdrawal Syndrome
What this study did
NCT01170117 · New York State Psychiatric Institute
2010-08 – 2017-06 · Anorexia Nervosa
What this study did
NCT01539733 · Amsterdam UMC, location VUmc
2010-03 – 2017-04 · Delirium, Advanced Cancer
What this study did
NCT02137616 · Central South University
2012-06 – 2014-12 · Psychotic Disorders
What this study did
NCT01990755 · University of Turin, Italy
2010-05 – 2013-05 · Anorexia Nervosa, Bulimia Nervosa
What this study did
NCT01496183 · State University of New York at Buffalo
2007-10 – 2013-04 · Healthy
What this study did
NCT00910988 · Washington University School of Medicine
2009-02 – 2012-06 · Hyperglycemia, Hyperlipidemia
What this study did
NCT00833300 · Richard Hall
2008-06 – 2011-11 · Delirium, Agitation
What this study did
NCT00741026 · Milton S. Hershey Medical Center
2008-08 – 2011-05 · Insulin Resistance, Diabetes Mellitus
What this study did
NCT01485692 · University of Sao Paulo
2009-02 – 2011-03 · Psychomotor Agitation
What this study did
NCT00737191 · Mayo Clinic
2008-08 – 2009-11 · Hematopoietic/Lymphoid Cancer, Pain, Unspecified Adult Solid Tumor, Protocol Specific
What this study did
NCT00512291 · M.D. Anderson Cancer Center
2005-06 – 2009-08 · Advanced Cancer
What this study did
NCT00275301 · University of Minnesota
2005-12 – 2008-12 · Borderline Personality Disorder
What this study did
NCT00699946 · The New England Baptist Hospital
2005-01 – 2007-10 · Delirium
What this study did
NCT00636896 · Neuropsychiatric Research Institute, Fargo, North Dakota
2006-07 – 2007-08 · Weight Gain
What this study did
NCT00203307 · Thomas Jefferson University
2004-05 – 2006-06 · Migraine
What this study did
NCT00625170 · Leiden University Medical Center
2004-05 – 2004-12 · Insulin Resistance, Dyslipidemia
What this study did
NCT00015548 · National Institute of Mental Health (NIMH)
2001-03 – 2004-10 · Alzheimer's Disease
What this study did
Used as active comparator (68)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (28)
Bipolar Disorder
NCT05303064 · Alkermes, Inc.
2022-06-30 – 2026-09 · Schizophrenia, Bipolar I Disorder
What this study did
NCT03187769 · Alkermes, Inc.
2017-06-08 – 2022-01-03 · Schizophrenia, Schizophreniform Disorders, Bipolar I Disorder
What this study did
NCT00490971 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
2006-05 – 2010-04 · Bipolar Disorder
What this study did
NCT00391222 · Janssen Pharmaceutica N.V., Belgium
2006-11 – 2009-04 · Bipolar Disorder
What this study did
NCT00159783 · Organon and Co
2005-07 – 2007-04 · Bipolar Disorder
What this study did
NCT00143182 · Organon and Co
2005-01-07 – 2006-06-28 · Bipolar Disorder
What this study did
NCT00159796 · Organon and Co
2004-12-14 – 2006-04-28 · Bipolar Disorder
What this study did
Schizophrenia
NCT02694328 · Alkermes, Inc.
2016-03-02 – 2018-11-07 · Schizophrenia
What this study did
NCT02634346 · Alkermes, Inc.
2015-12 – 2017-06-07 · Schizophrenia
What this study did
NCT01617200 · Forest Laboratories
2012-12 – 2015-03 · Schizophrenia
What this study did
NCT01617187 · Organon and Co
2012-12-04 – 2014-09-09 · Schizophrenia
What this study did
NCT00615433 · Sumitomo Pharma America, Inc.
2008-01 – 2010-01 · Schizophrenia
What this study did
NCT00645099 · Janssen-Cilag International NV
2007-10 – 2009-04 · Schizophrenia
What this study did
NCT00864045 · H. Lundbeck A/S
2007-03 – 2008-05 · Schizophrenia
What this study did
NCT00759421 · H. Lundbeck A/S
2006-10 – 2008-04 · Schizophrenia
What this study did
NCT00759460 · H. Lundbeck A/S
2007-03 – 2008-04 · Schizophrenia
What this study did
NCT00265343 · Organon and Co
2005-12 – 2008-01 · Schizophrenia
What this study did
NCT00396565 · Janssen Pharmaceutical K.K.
2006-07 – 2007-11 · Schizophrenia
What this study did
NCT00212836 · Organon and Co
2005-04-21 – 2007-08-02 · Schizophrenia
What this study did
NCT00156091 · Organon and Co
2005-04 – 2007-06 · Schizophrenia
What this study did
NCT00212771 · Organon and Co
2004-09 – 2006-10 · Schizophrenia, Schizoaffective Disorder
What this study did
NCT00156117 · Organon and Co
2005-05-12 – 2006-05-30 · Schizophrenia
What this study did
NCT00212784 · Organon and Co
2003-09-04 – 2006-03-15 · Schizophrenia, Schizoaffective Disorder
What this study did
NCT00151424 · Organon and Co
2005-02-15 – 2006-02-06 · Schizophrenia
What this study did
NCT00712686 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2000-06 – 2003-12 · Schizophrenia
What this study did
Phase 2/3 (1)
Schizophrenia
NCT01129674 · Denovo Biopharma LLC
2010-06 – 2012-10 · Schizophrenia
What this study did
Phase 2 (12)
Schizophrenia
NCT02088060 · Central Institute of Mental Health, Mannheim
2015-12-08 – 2024-09-16 · Schizophrenia
What this study did
NCT00816894 · Herzog Hospital
2009-01 – 2013-02 · Schizophrenia
What this study did
NCT01234779 · Hoffmann-La Roche
2011-02 – 2012-09 · Schizophrenia
What this study did
NCT00988728 · Merck Sharp & Dohme LLC
2011-02 – 2012-07 · Schizophrenia
What this study did
NCT00845026 · Denovo Biopharma LLC
2009-03 – 2010-12 · Schizophrenia
What this study did
NCT00827918 · Merck Sharp & Dohme LLC
2009-03 – 2010-04 · Schizophrenia
What this study did
NCT00728195 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
2008-11 – 2010-02 · Schizophrenia
What this study did
NCT00770744 · H. Lundbeck A/S
2008-09 – 2009-11 · Schizophrenia
What this study did
NCT00520923 · Denovo Biopharma LLC
2007-09 – 2008-10 · Schizophrenia
What this study did
NCT00483964 · Q.Mundewadi Ayurvedic Research & Charitable Trust
2005-09 – 2007-09 · Schizophrenia
What this study did
NCT00149292 · Denovo Biopharma LLC
2005-08-23 – 2006-07-17 · Schizophrenia
What this study did
Other / comorbidity
NCT04529226 · Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
2020-11-26 – 2025-12-30 · Psychosis, Intellectual Disability
What this study did
Phase 1 (9)
Schizophrenia
NCT05542264 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2022-11-15 – 2024-02-12 · Schizophrenia
What this study did
NCT05402111 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2022-06-13 – 2023-09-27 · Schizophrenia
What this study did
Other / comorbidity
NCT07921966 · Neurelis, Inc.
2026-10-16 – 2027-01-14 · Healthy Adult Participants
What this study did
NCT05123976 · Joint Stock Company "Farmak"
2020-10-21 – 2020-11-30 · Pharmacokinetics
What this study did
NCT03624322 · Impel Pharmaceuticals
2018-08-05 – 2018-10-03 · Acute Agitation
What this study did
NCT02922426 · Alkermes, Inc.
2016-09 – 2017-07-20 · Healthy Volunteers
What this study did
NCT00648921 · Mylan Pharmaceuticals Inc
2003-06 – 2003-07 · Healthy
What this study did
NCT00647777 · Mylan Pharmaceuticals Inc
2003-06 – 2003-07 · Healthy
What this study did
NCT00647972 · Mylan Pharmaceuticals Inc
2003-05 – 2003-05 · Healthy
What this study did
Phase 4 (14)
Bipolar Disorder
NCT02562287 · Hospital de Clinicas de Porto Alegre
2015-10 – 2020-12 · Bipolar Disorder
What this study did
NCT00329108 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2006-11 – 2008-01 · Acute Mania, Bipolar Disorder, Manic
What this study did
Schizophrenia
NCT03304457 · All India Institute of Medical Sciences, Bhubaneswar
2017-08-25 – 2018-03-25 · Schizophrenia
What this study did
NCT02282085 · Matt Byerly
2014-12 – 2017-12 · Schizophrenia
What this study did
NCT01248195 · Rene Kahn
2011-05 – 2016-04 · Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder
What this study did
NCT01157351 · Janssen Scientific Affairs, LLC
2010-05 – 2013-12 · Schizophrenia
What this study did
NCT01193166 · Ortho-McNeil Janssen Scientific Affairs, LLC
2010-08 – 2012-09 · Schizophrenia
What this study did
NCT00330863 · Northwell Health
2006-05 – 2011-01 · Schizophrenia, Schizoaffective Disorder
What this study did
NCT00423878 · National Institute of Mental Health (NIMH)
2007-01 – 2010-03 · Schizophrenia, Schizoaffective Disorder
What this study did
NCT00508157 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2007-11-01 – 2009-03-01 · Metabolic Syndrome, Schizophrenia
What this study did
NCT00654576 · Central South University
2005-02 – 2007-12 · Schizophrenia
What this study did
NCT00419653 · University of Jena
2003-01 – 2007-09 · Schizophrenia
What this study did
Other / comorbidity
NCT03857581 · Augusta University
2020-07 – 2021-07 · Psychosis, Substance Use Disorders
What this study did
NCT00806234 · Johns Hopkins University
2009-01 – 2014-03 · Psychotic Disorders
What this study did
Early phase / not applicable (4)
Schizophrenia
NCT02918825 · Beijing HuiLongGuan Hospital
2016-09-01 – 2017-09-30 · Schizophrenia
What this study did
NCT02192723 · Beijing HuiLongGuan Hospital
2012-06 – 2014-06 · Schizophrenia
What this study did
NCT00349973 · University of Maryland, Baltimore
2001-05 – 2011-09 · Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
What this study did
Other / comorbidity
NCT04341467 · Tianjin Anding Hospital
2019-12-01 – 2024-05 · BPSD, Amisulpride, Olanzapine, Dementia of the Alzheimer Type
What this study did
Studied as part of a combination product (8)

Studies of a fixed-dose combination that contains this drug. The combination is the product under test, so these are that product's evidence rather than this one's; the link is kept because the drug really was administered.

Phase 3 (2)
Schizophrenia
NCT02374567 · Hannover Medical School
2015-01 – 2017-06-28 · Dementia, Depression, Schizophrenia, Psychosomatic Disorders, Anxiety Disorders
What this study did
Other / comorbidity
NCT00958568 · Eli Lilly and Company
2009-08 – 2012-03 · Treatment Resistant Depression
What this study did
Phase 1 (1)
Other / comorbidity
NCT05547100 · Alkermes, Inc.
2022-09-14 – 2022-11-19 · Focus of Study is on Healthy Lactating Women
What this study did
Phase 4 (5)
Bipolar Disorder
NCT06740890 · New York State Psychiatric Institute
2025-06-26 – 2027-04 · Schizophenia Disorder, Schizoaffective Disorder, Bipolar Disorder I or II, Bipolar Disorder NOS
What this study did
NCT00188942 · University Health Network, Toronto
2005-02 – 2009-06 · Major Depressive Disorder
What this study did
Other / comorbidity
NCT04876521 · All India Institute of Medical Sciences, Bhubaneswar
2019-10-14 – 2021-06-30 · Post-Schizophrenic Depression
What this study did
NCT00844857 · Eli Lilly and Company
2009-04 – 2012-02 · Bipolar Depression
What this study did
NCT00000373 · University of Florida
1992-09 – 2003-07 · Obsessive-Compulsive Disorder
What this study did
Appears in other studies (18)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (8)
Schizophrenia
NCT00970281 · Eli Lilly and Company
2009-09 – 2011-04 · Schizophrenia
What this study did
NCT00640510 · Eli Lilly and Company
2008-03 – 2008-07 · Schizophrenia
What this study did
NCT00237913 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2004-07 – 2005-08 · Schizophrenia
What this study did
NCT00088478 · Eli Lilly and Company
2004-06 – 2005-04 · Schizophrenia
What this study did
NCT00159770 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2001-11 – 2004-09 · Schizophrenia, Schizoaffective Disorder, Psychotic Disorders
What this study did
Other / comorbidity
NCT07246187 · Mercy Bon Secours Saint Vincent Medical Center
2025-11-06 – 2026-10-01 · Cannabinoid Hyperemesis Syndrome
What this study did
NCT03578081 · Alliance for Clinical Trials in Oncology
2018-11-20 – 2023-05-01 · Malignant Neoplasm
What this study did
Phase 2 (3)
Schizophrenia
NCT03557931 · Astellas Pharma Global Development, Inc.
2018-07-13 – 2019-10-21 · Schizophrenia
What this study did
NCT01903837 · Alkermes, Inc.
2013-06 – 2015-03 · Schizophrenia
What this study did
NCT00509067 · Georgetown University
2007-11 – 2011-03 · Schizophrenia
What this study did
Phase 1 (1)
Schizophrenia
NCT00094640 · Eli Lilly and Company
— · Schizophrenia, Schizoaffective Disorder
What this study did
Phase 4 (4)
Bipolar Disorder
NCT07047651 · Dr. Stavroula Rakitzi
2025-06-04 – 2027-12-20 · Treatment Resistant Schizophrenia, Treatment Resistant Bipolar Disorder
What this study did
Schizophrenia
NCT02040883 · Qingyun Yin
2014-02 – 2014-12 · Schizophrenia
What this study did
NCT00981526 · University of Massachusetts, Worcester
2009-03 – 2012-05 · Schizophrenia, Schizoaffective Disorder
What this study did
NCT00304616 · Korea Otsuka Pharmaceutical Co., Ltd.
2004-10 – 2007-10 · Schizophrenia
What this study did
Early phase / not applicable (2)
Schizophrenia
NCT03019887 · Juntendo University
2011-04 – 2017-01 · Schizophrenia Relapse
What this study did
NCT00493233 · Centre for Addiction and Mental Health
2006-11 – 2008-12 · Schizophrenia
What this study did

Competitive landscape

This mechanism is crowded: 24 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Schizophrenia: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Olanzapine (Zyprexa): this drugApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Partial signal
NCT03510325: Phase 2 symptomatic response (≥40% PANSS reduction) among 111 first-episode-treatment nonresponders re-randomized to second-line therapy: olanzapine 31.7% (13/41) vs amisulpride 44.7% (17/38) vs clozapine 62.5% (20/32); chi-square=6.9, P=.03 missed
Aripiprazole (Abilify Maintena)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D2/D3 and serotonin 5-HT1A receptor, Dopamine D2 receptor (partial agonist)Reliable signal
NCT03172871: LS mean change from baseline to Week 10 in PANSS Total Score: -33.6 (aripiprazole once-monthly, AOM) vs -34.8 (oral aripiprazole); difference -1.2 (95% CI: -4.1, 1.7), within the pre-defined non-inferiority margin
NCT00706654: Impending relapse by week 26: aripiprazole once-monthly 400 mg 7.12% vs oral aripiprazole 10-30 mg 7.76% (non-inferior); low-dose depot reference arm 21.80%
Aripiprazole (Abilify)ApprovedSmall moleculeDopamine D2/D3 and serotonin 5-HT1A receptorPartial signal
NCT00712686: Mean change in PANSS Total Score from baseline to Week 6: aripiprazole -24.6 vs olanzapine -29.5 (random regression model); treatment difference 4.9 points, 95% CI 2.2-7.6, exceeding the pre-specified 6-point non-inferiority margin -- aripiprazole did not reach non-inferiority (olanzapine was statistically superior). Aripiprazole showed significantly less weight gain at Week 26: +0.13 kg vs +4.30 kg for olanzapine, and fewer patients with significant weight gain (21% vs 40%, p<.05).
Aripiprazole Lauroxil (Aristada Initio)ApprovedSmall moleculeDopamine D2/D3 and serotonin 5-HT1A receptornot yet gradedNo reviewed efficacy summary in this indication
Aripiprazole Lauroxil (Aristada)ApprovedSmall moleculeDopamine D2/D3 and serotonin 5-HT1A receptorReliable signal
NCT01469039: The Change From Baseline at Day 85 in Positive and Negative Syndrome Scale (PANSS) Total Score (Data collected from baseline to day 85): Aripiprazole Lauroxil 441 mg -20.9 units on a scale (Standard Error 1.39) | Aripiprazole Lauroxil 882 mg -21.8 units on a scale (Standard Error 1.35) vs Placebo -9.8 units on a scale (Standard Error 1.39)
AsenapineApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Partial signal
NCT00212771: Mean PANSS total score changes during first year of treatment were - 37.0 asenapine and - 35.3 olanzapine, with further changes of 1.6 asenapine and - 0.8 olanzapine at the extension study endpoint
NCT00212784: Change in total PANSS score (52-week active-controlled trial): asenapine -21.0 vs olanzapine -27.5, difference P<0.0001. missed
Brexpiprazole (Rexulti)ApprovedSmall moleculeDopamine D2/D3 and serotonin 5-HT1A receptorPartial signal
NCT03198078: Change from baseline to Week 6 in PANSS total score: brexpiprazole -22.8 (SE 1.5) vs placebo -17.4 (SE 1.6); least-squares mean difference -5.33, 95% CI -9.55 to -1.10, p=0.014
NCT01396421: Change in PANSS total score at Week 6 vs placebo: brexpiprazole 2 mg treatment difference -8.72; 4 mg treatment difference -7.64 (both statistically significant).
Cariprazine (Vraylar)ApprovedSmall moleculeDopamine D3/D2 receptor (partial agonist)Reliable signal
NCT01104766: Measurement of Schizophrenia Symptoms: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score. (Baseline to Week 6): Cariprazine 3.0 mg -20.2 Units on a Scale (Standard Error 1.5) | Cariprazine 6.0mg -23 Units on a Scale (Standard Error 1.5) vs Placebo -14.3 Units on a Scale (Standard Error 1.5) | Aripiprazole 10.0 mg -21.2 Units on a Scale (Standard Error 1.4)
NCT01104779: Measurement of Schizophrenia Symptoms: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score (Baseline to Week 6): Cariprazine (3-6 mg/Day) -22.8 Units on a Scale (Standard Error 1.6) | Cariprazine (6-9 mg/Day) -25.9 Units on a Scale (Standard Error 1.7) vs Placebo -16 Units on a Scale (Standard Error 1.6)
ClozapineApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Weak signal
NCT03510325: Primary 1, symptomatic response (40% or more PANSS total reduction) in phase 2 among 111 re-randomized nonresponders: clozapine 62.5% (20/32) vs amisulpride 44.7% (17/38) vs olanzapine 31.7% (13/41) (chi-square 6.9; P=.03), met. Primary 2, time to all-cause discontinuation: the paper reports no clear difference between treatment groups, missed.
Haloperidol
ApprovedUS marketing discontinued
Small moleculeDopamine D2 receptor (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Iloperidone (Fanapt)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Partial signal
NCT00254202: Change in PANSS total score at day 28: iloperidone 24 mg/day -12.0 (SE 1.03) vs placebo -7.1 (SE 1.48) vs ziprasidone -12.3 (SE 1.44) (CT.gov); iloperidone was superior to placebo on the primary (FANAPT label, Study 2).
Lumateperone (Caplyta)ApprovedSmall moleculeSerotonin 5-HT2A / dopamine D1-D2 receptorPartial signal
NCT04959032: Study 304 (NCT04959032), time to relapse during double-blind phase: HR 0.37 (95% CI 0.22-0.65), 63% relapse-risk reduction vs placebo (p=0.0002); relapse rate 16.4% (18 relapses) lumateperone vs 38.6% (44 relapses) placebo
NCT02469155: Change From Baseline to Week 6 in Positive and Negative Syndrome Scale (PANSS) Total Score (6 weeks): Lumateperone 14 mg (ITI-007 20 mg Tosylate) -15 units on a scale (Standard Error 1.27) | Lumateperone 42 mg (ITI-007 60 mg Tosylate) -14.6 units on a scale (Standard Error 1.23) vs Placebo -15.1 units on a scale (Standard Error 1.21) | Risperidone -20.5 units on a scale (Standard Error 1.33) missed
LurasidoneApprovedSmall moleculeDopamine D2/D3 receptor + 5-HT7 receptor, Dopamine D2 and serotonin 5-HT2A receptors (antagonist)Reliable signal
NCT03465787: Change in PANSS total score at week 6 (prespecified primary analysis in the per-protocol set): -26.42±2.02 lurasidone vs -27.33±2.01 quetiapine XR (adjusted mean±SE); difference -0.91 (95% CI -6.35 to 4.53); lower limit above the -8.99 non-inferiority margin, met. The ITT set analysis also showed non-inferiority.
NCT00549718: Change in Total PANSS Score From Baseline to the End of the Double Blind Phase (6 weeks): Lurasidone 40mg -19.2 scores on a scale (95% CI -22.6 to -15.7) | Lurasidone 80mg -23.4 scores on a scale (95% CI -26.9 to -19.9) | Lurasidone 120mg -20.5 scores on a scale (95% CI -24 to -17.1) vs Placebo -17 scores on a scale (95% CI -20.5 to -13.6)
Milsaperidone (VHX-896)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Weak signalNo reviewed efficacy summary in this indication
Olanzapine (Weltruza)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A/5-HT2C receptors (antagonist)Reliable signal
NCT05693935: Double-blind Period: Change in the Positive and Negative Syndrome Scale (PANSS) Total Score From Baseline to Week 8 (Baseline, Week 8): Double-blind: TV-44749 318 mg -21.91 units on a scale (95% CI -25.13 to -18.7) | Double-blind: TV-44749 425 mg -23.44 units on a scale (95% CI -26.52 to -20.36) | Double-blind: TV-44749 531 mg -21.93 units on a scale (95% CI -25.01 to -18.85) vs Double-blind: Placebo -12.17 units on a scale (95% CI -15.34 to -8.99)
Olanzapine (Zyprexa Relprevv)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Reliable signal
NCT00088478: 8-week acute study, olanzapine long-acting injection (210 mg/2wk, 300 mg/2wk, 405 mg/4wk) vs placebo: PANSS total score decrease significantly greater for all three LAI regimens vs placebo (p<.001 each).
NCT00320489: Median Time to Discontinuation for Any Reason (Excluding Sponsor Decision) (Baseline up to 104 weeks): Olanzapine Pamoate Depot 644.5 Days (IQR 162 to 740) vs Oral Olanzapine 677.5 Days (IQR 169.5 to 740) missed
Olanzapine / Samidorphan (Lybalvi)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist); mu-opioid receptor (antagonist)Reliable signal
NCT03187769: Percent change from baseline in body weight at Week 12: 4.91% ALKS 3831 vs 6.77% olanzapine; least-squares mean difference −1.87 percentage points (95% CI −3.33 to −0.41; p=0.012).
NCT02634346: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 4 (4 weeks): ALKS 3831 -23.9 units on a scale (Standard Error 1.28) vs Olanzapine -22.8 units on a scale (Standard Error 1.29) vs Placebo -17.5 units on a scale (Standard Error 1.32)
Paliperidone (Invega)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet graded
NCT04072575: Number of Participants With Relapse (Up to Day 730): Total Paliperidone Palmitate 6-month (PP6M) 700 or 1000 mg eq. 7/178 phase 3 result · pivotal pending
Paliperidone Palmitate (Erzofri)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Partial signalNo reviewed efficacy summary in this indication
Paliperidone Palmitate (Invega Sustenna)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Partial signal
NCT02431702: Treatment failure in Part II (9 months): paliperidone palmitate 29.5% vs oral antipsychotics 24.8%, P=0.377; extended 18-month analysis 28.6% vs 44.4%, P=0.080 (DREaM, Schizophr Res 2022). missed
NCT00101634: PANSS total improved vs placebo in all three fixed-dose groups (p=0.02 for 25 and 50 mg equiv., p<0.001 for 100 mg equiv.).
Paliperidone Palmitate (Invega Trinza)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Weak signal
NCT04072575: Number of Participants With Relapse (Up to Day 730): Total Paliperidone Palmitate 6-month (PP6M) 700 or 1000 mg eq. 7/178
NCT02713282: Symptomatic remission (Andreasen PANSS criteria) at LOCF/Month 12 endpoint: 172/303 patients, 56.8% (95% CI 51.0-62.4)
Perseris
ApprovedUS marketing discontinued
Small moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Reliable signal
NCT02109562: Mixed Model for Repeated Measures (MMRM) Analysis of Change From Baseline to End of Treatment in the Positive and Negative Syndrome Scale (PANSS) Total Score (Day 1 prior to treatment (Baseline), Days 15, 29, 43 and 57 or early discontinuation): RBP-7000 90 mg -15.367 units on a scale (Standard Error 1.223) | RBP-7000 120 mg -16.456 units on a scale (Standard Error 1.2073) vs Placebo -9.219 units on a scale (Standard Error 1.2162)
Quetiapine (Seroquel XR)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Weak signal
NCT00640601: Percentage of Subjects With Improved Clinical Benefit From Assessment of Clinical Global Impression-Clinical Benefit (CGI-CB) Scale From Baseline to Week 24 or End of Study (Baseline to 24 weeks (or end of study)): Seroquel XR 56.88% (95% CI 50.8 to 62.8)
Quetiapine (Seroquel)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Partial signal
NCT00305422: Global cognition improved vs baseline at week 12 on quetiapine (p<0.01) and risperidone (p<0.05).
Risperidone (Risperdal Consta)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Reliable signal
NCT00253136: Clinical improvement (>=20% PANSS total score reduction): 47% (Risperdal Consta 25mg) vs 17% (placebo); design (randomized, double-blind, placebo-controlled, 25/50/75mg arms, 12 weeks, Nov 1999-Dec 2000) and this was the pivotal FDA-registration trial for Risperdal Consta, matching NCT00253136's CT.gov record exactly.
Risperidone (Risperdal)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Risperidone (Rykindo)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Weak signalNo reviewed efficacy summary in this indication
Risperidone (Uzedy)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Reliable signal
NCT03503318: Time to Impending Relapse (Number of Participants With Impending Relapse) for Intent-to-treat [ITT] Analysis Set (From randomization up to 108 weeks): TV-46000 q1m 13/183 | TV-46000 q2m 23/179 vs Placebo 53/181
Xanomeline / Trospium Chloride (Cobenfy)ApprovedSmall moleculeMuscarinic M1/M4 receptor (agonist/antagonist combination)Reliable signal
NCT04738123: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 5 (From baseline up to Week 5): KarXT -20.6 Score on a scale (Standard Error 1.584) vs Placebo -12.2 Score on a scale (Standard Error 1.552)
NCT04659161: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 5 (Baseline and Week 5): KarXT -21.2 score on a scale (Standard Deviation 1.652) vs Placebo -11.6 score on a scale (Standard Deviation 1.6)
ZiprasidoneApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Partial signal
NCT00403546: Change from baseline in PANSS total score at Week 8, high-dose ziprasidone (320 mg/day) vs standard dose (160 mg/day plus placebo capsules): -8.62 vs -5.48, mixed-model difference -1.37 (95% CI -7.20 to 4.45), p=0.642. No registered primary favoured the high dose; the Simpson-Angus extrapyramidal score was worse on the high dose at Week 2 (difference 1.02, 95% CI 0.08 to 1.95, p=0.033). missed
NCT00159770: Ziprasidone non-inferior to the olanzapine/risperidone/quetiapine group on total PANSS (margin 7 units; P<0.0001).
Cariprazine (Chengdu Kanghong)Phase 3Small moleculeDopamine D3/D2 receptor (partial agonist)not yet gradedNo reviewed efficacy summary in this indication
Cariprazine (QLM1016)Phase 3Small moleculeDopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 receptor (partial agonist)not yet gradedNo reviewed efficacy summary in this indication
Dexmedetomidine (Igalmi)Phase 3Small moleculeAlpha-2 adrenergic receptor (agonist)Reliable signal
NCT04268303: Change From Baseline in the Positive and Negative Syndrome Scale- Excited Component (PEC) Total Score (Baseline and 2 hours): 120 Micrograms — Baseline: 17.5 score on a scale (Standard Deviation 2.46); 2 Hours: -8.4 score on a scale (Standard Deviation 4.83) | 180 Micrograms — Baseline: 17.6 score on a scale (Standard Deviation 2.69); 2 Hours: -10.4 score on a scale (Standard Deviation 4.34) vs Placebo — Baseline: 17.6 score on a scale (Standard Deviation 2.26); 2 Hours: -4.7 score on a scale (Standard Deviation 4.69)
NCT05658510: Primary endpoint (SERENITY III Part 1, change from baseline in PEC total score at 2 hours), drug vs placebo: p=0.077, not statistically significant.
DireclidinePhase 3Small moleculeMuscarinic M4 receptorPartial signal
NCT05545111: PANSS total score at week 6: 7.5-point placebo-adjusted improvement (p=0.011, effect size 0.61) with 20 mg once daily; 18.2-point improvement from baseline
HS-10380Phase 3Small moleculeDopamine D2/D3 and serotonin 5-HT1A/5-HT2A receptors (multi-target)Partial signalNo reviewed efficacy summary in this indication
LB-102 (methylated Amisulpride)Phase 3Small moleculeDopamine D2/D3 receptor + 5-HT7 receptorReliable signal
NCT06179108: Change From Baseline to Week 4 in the PANSS Total Score (Baseline to Day 28 (4 weeks)): LB-102, 50 mg QD -14.28 score on a scale ± 1.097 vs LB-102, 75 mg QD -13.95 score on a scale ± 1.108 vs LB-102, 100 mg -16.08 score on a scale ± 1.906 vs Placebo Comparator -9.27 score on a scale ± 1.078; p=0.0009 (LB-102, 50 mg QD vs Placebo Comparator), p=0.0022 (LB-102, 75 mg QD vs Placebo Comparator), p=.0017 (LB-102, 100 mg vs Placebo Comparator)
Loxapine (Adasuve)Phase 3Small moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Reliable signal
NCT00628589: Change in PANSS-EC From Baseline (Baseline and 2 hours): Inhaled Loxapine 5 mg -8.1 units on a scale (Standard Deviation 5.17) | Inhaled Loxapine 10 mg -8.6 units on a scale (Standard Deviation 4.37) vs Inhaled Placebo -5.5 units on a scale (Standard Deviation 4.92)
Olanzapine / Samidorphan (Qilu)Phase 3Small moleculeDopamine D2 and serotonin 5-HT2A/5-HT2C receptors (antagonist); mu-opioid receptor (antagonist), Dopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
RoluperidonePhase 3Small moleculeSigma-2 receptor complex, Serotonin 5-HT2A receptor (antagonist / inverse agonist)Partial signal
NCT03397134: Change From Baseline to Week 12 in PANSS Marder Negative Symptoms Factor Score (NSFS) (Baseline, Week 2, Week 4, Week 8, and Week 12): Roluperidone 32 mg — Baseline: 25.2 score on a scale (Standard Deviation 3.43); Change from Baseline to Week 2: -1.2 score on a scale (Standard Deviation 2.22); Change from Baseline to Week 4: -2.6 score on a scale (Standard Deviation 2.57); Change from Baseline to Week 8: -3.4 score on a scale (Standard Deviation 3.49); Change from Baseline to Week 12: -3.7 score on a scale (Standard Deviation 3.2) | Roluperidone 64 mg — Baseline: 25.3 score on a scale (Standard Deviation 3.26); Change from Baseline to Week 2: -1.7 score on a scale (Standard Deviation 2.47); Change from Baseline to Week 4: -2.8 score on a scale (Standard Deviation 2.92); Change from Baseline to Week 8: -3.8 score on a scale (Standard Deviation 3.32); Change from Baseline to Week 12: -4.5 score on a scale (Standard Deviation 3.85) vs Placebo — Baseline: 24.3 score on a scale (Standard Deviation 3.01); Change from Baseline to Week 2: -1.2 score on a scale (Standard Deviation 2.46); Change from Baseline to Week 4: -1.8 score on a scale (Standard Deviation 2.99); Change from Baseline to Week 8: -2.8 score on a scale (Standard Deviation 3.44); Change from Baseline to Week 12: -3.5 score on a scale (Standard Deviation 3.97) missed
UlotarontPhase 3Small moleculeTAAR1 (trace amine-associated receptor 1)Partial signal
NCT04092686: Change From Baseline in PANSS Total Score at Week 6 (Baseline, Week 6): SEP-363856 75mg -16.4 score on a scale (Standard Error 1.49) | SEP-363856 100mg -18.1 score on a scale (Standard Error 1.5) vs Placebo -14.3 score on a scale (Standard Error 1.47) missed
NCT04072354: Change From Baseline in PANSS Total Score at Week 6 (Baseline, Week 6): Adults: SEP-363856 50mg -16.9 score on a scale (Standard Error 1.57) | Adults: SEP-363856 75mg -19.6 score on a scale (Standard Error 1.56) vs Adults: Placebo -19.3 score on a scale (Standard Error 1.55) missed
ANAVEX3-71Phase 2Small moleculeSigma-1 receptor / muscarinic receptor (dual)Partial signal
NCT06245213: ANAVEX3-71-SZ-001 (NCT06245213) achieved its primary endpoint: ANAVEX3-71 was safe and well-tolerated, with no serious TEAEs and no severe TEAEs in either Part A or Part B.
Balipodect (TAK-063)Phase 2Small moleculePhosphodiesterase 10A (PDE10A)Partial signal
NCT02477020: Change From Baseline in the Positive and Negative Symptom Scale (PANSS) Total Score at Week 6 (Baseline and Week 6): TAK-063 -19.54 score on a scale (Standard Error 2.412) vs Placebo -14.08 score on a scale (Standard Error 2.474) missed
Betovumeline / Fesoterodine (ML-007C-MA)Phase 2Small moleculeMuscarinic M1 and M4 receptors (agonist)Partial signal
NCT07038876: PANSS total score change at week 5 vs placebo (mITT): 210/3 mg BID, LS mean difference -4.5 points, Cohen's d 0.37, p=0.015, met. 330/6 mg QD, numerical improvement, not statistically significant (no figure given), missed.
BrenipatidePhase 2PeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
CPL500036Phase 2Small moleculePDE10AReliable signal
NCT05278156: Change from baseline in PANSS positive subscale at Day 28 (Week 4): 20 mg dose improved 3.7 points (p<0.001, Cohen's d=0.73); 40 mg dose improved 6.3 points (p<0.001, Cohen's d=1.38)
EmraclidinePhase 2Small moleculeMuscarinic M4 receptorPartial signal
NCT05227703: Change From Baseline at Week 6 in the Positive and Negative Syndrome Scale (PANSS) Total Score (Baseline through Week 6): Emraclidine 15mg QD -18.5 score on a scale (95% CI -22 to -15) | Emraclidine 30mg QD -14.2 score on a scale (95% CI -17.5 to -10.8) vs Placebo -16.1 score on a scale (95% CI -19.4 to -12.8) missed
GXV813Phase 2Small molecule—not yet gradedNo reviewed efficacy summary in this indication
LY03020Phase 2Small molecule5-HT2C/TAAR1 receptorWeak signalNo reviewed efficacy summary in this indication
NBI-1117570Phase 2Small moleculeMuscarinic M1 and M4 receptors (agonist)not yet gradedNo reviewed efficacy summary in this indication
Tazbentetol (SPG302)Phase 2Small moleculeDendritic spine densitynot yet gradedNo reviewed efficacy summary in this indication
Ublituximab (Briumvi)Phase 2Monoclonal antibodyCD20not yet gradedNo reviewed efficacy summary in this indication
VV119Phase 2Small moleculeDopamine and serotonin receptors (multi-target antipsychotic)not yet gradedNo reviewed efficacy summary in this indication
Cariprazine Long-Acting Injection (Mapi Pharma)Phase 1/2Small moleculeDopamine D3/D2 receptor (partial agonist)not yet gradedNo reviewed efficacy summary in this indication
JX11502MAPhase 1/2Small moleculeDopamine D3/D2 receptor (partial agonist)Weak signal
NCT05233657: JX11502MA was generally well tolerated at a single dose of 0.25 to 3 mg. The most common treatment-emergent adverse events were somnolence (56.3%), nausea (21.9%), dizziness (18.8%), vomiting (18.8%) and hiccups (18.8%).
AticaprantPhase 1Small moleculeKappa-opioid receptor (inhibitor), Kappa opioid receptor (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Brexpiprazole Long-Acting Injection (Kelun)Phase 1Small moleculeDopamine D2/D3 and serotonin 5-HT1A receptornot yet gradedNo reviewed efficacy summary in this indication
HS-10509Phase 1Small molecule—Partial signalNo reviewed efficacy summary in this indication
LY03017Phase 1Small moleculeSerotonin 5-HT2A receptor (antagonist / inverse agonist), 5-HT2A/5-HT2C, 5-HT2A/2C receptorWeak signalNo reviewed efficacy summary in this indication
NTX-253Phase 1Small moleculeMuscarinic M4 receptornot yet gradedNo reviewed efficacy summary in this indication
Risperidone (QUAR)Phase 1Small moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Weak signalNo reviewed efficacy summary in this indication
SEP-380135Phase 1Small molecule—Weak signalNo reviewed efficacy summary in this indication
Paliperidone Palmitate (CSPC)
—(overall)
Small moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Aripiprazole (Abilify MyCite)DiscontinuedCombinationDopamine D2 and serotonin 5-HT1A receptors (partial agonist); serotonin 5-HT2A receptor (antagonist)Weak signal
NCT03892889: Percentage of Participants With Inpatient Psychiatric Hospitalization (Retrospective Period [Month -6 to Baseline (Day 1)] up to Prospective Period (Day 1 to Month 3)): Abilify MyCite® 0%
AVP-786DiscontinuedCombinationsigma-1/NMDAnot yet gradedNo reviewed efficacy summary in this indication
Clozapine (Fazaclo)DiscontinuedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Extended-Release Niacin (Niaspan)DiscontinuedSmall moleculeGPR109A (HCAR2)not yet gradedNo reviewed efficacy summary in this indication
NeloniclineDiscontinuedSmall moleculenicotinic acetylcholine receptor alpha7 (alpha7 nAChR)Partial signal
NCT01655680: MCCB neurocognitive composite, change from baseline to week 12 (primary analysis, ABT-126 50 mg vs placebo): +2.66 (±0.54) vs +2.46 (±0.56), P>0.05; 432 randomized. The UPSA-2ER key secondary also showed no significant difference. missed
Risperidone (Risvan)DiscontinuedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Reliable signal
NCT03160521: PANSS Total Score Mean Change From Baseline to Endpoint (Day 1 (Baseline) and Day 85 (or the last post-baseline assessment)): Risperidone ISM 75 mg -24.6 units on a scale (Standard Error 1.51) | Risperidone ISM 100 mg -24.7 units on a scale (Standard Error 1.54) vs Placebo -11 units on a scale (Standard Error 1.56)
Rosiglitazone (Avandia)DiscontinuedSmall moleculePPAR-gammanot yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(24 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Olanzapine (Zyprexa) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (5)
December 2026 (5)
Phase 2Anorexia Nervosa with Significantly Low Body WeightEnrolling by invitation
Est. primary completion 2026-12 · NCT05170919 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2026-12-01 · NCT06554613 · CT.gov ↗
What to watch
Phase 3Oncology Patients Receiving Chemotherapy, Cachexia-Anorexia Syndrome, OncologyRecruiting
Est. primary completion 2026-12-28 · NCT07633236 · CT.gov ↗
What to watch
Phase 1/2Depression, SequestraRecruiting
Est. primary completion 2026-12-31 · NCT05814640 · CT.gov ↗
What to watch
Early phase / not applicableInsulin Resistance, Menstrual Cycle, Type 2 Diabetes, AntipsychoticsActive not recruiting
Est. primary completion 2026-12-31 · NCT06251635 · CT.gov ↗
What to watch
2027 (14)
February 2027 (1)
Phase 1SchizophreniaActive not recruiting
Est. primary completion 2027-02-10 · NCT03781115 · CT.gov ↗
What to watch
March 2027 (1)
Phase 3Advanced Cancer, Olanzapine, Progression Free SurvivalRecruiting
Est. primary completion 2027-03-20 · NCT06338683 · CT.gov ↗
What to watch
May 2027 (1)
Phase 2SchizophreniaRecruiting
Est. primary completion 2027-05 · NCT06821945 · CT.gov ↗
What to watch
June 2027 (2)
Phase 2Breast CancerRecruiting
Est. primary completion 2027-06-03 · NCT07455955 · CT.gov ↗
What to watch
Phase 2Advanced Malignant Solid Neoplasm, Advanced Biliary Tract Carcinoma, Advanced Esophageal Carcinoma, Metastatic Esophageal Carcinoma …Recruiting
Est. primary completion 2027-06-30 · NCT05705492 · CT.gov ↗
What to watch
August 2027 (1)
Phase 1Germ Cell CancerNot yet recruiting
Est. primary completion 2027-08 · NCT07662200 · CT.gov ↗
What to watch
September 2027 (4)
Phase 3Multiple MyelomaRecruiting
Est. primary completion 2027-09 · NCT07413809 · CT.gov ↗
What to watch
Phase 3Out-Of-Hospital Cardiac Arrest, Post-Cardiac Arrest SyndromeActive not recruiting
Est. primary completion 2027-09 · NCT05895838 · CT.gov ↗
What to watch
Early phase / not applicableOlanzapine, Breast Cancer, DexamethasoneRecruiting
Est. primary completion 2027-09-29 · NCT07743827 · CT.gov ↗
What to watch
Phase 4SchizophreniaRecruiting
Est. primary completion 2027-09-30 · NCT04478838 · CT.gov ↗
What to watch
October 2027 (1)
Phase 3Multiple Myeloma, Autologous Stem Cell TransplantationRecruiting
Est. primary completion 2027-10 · NCT06588413 · CT.gov ↗
What to watch
November 2027 (1)
Phase 3Misuse, OpioidActive not recruiting
Est. primary completion 2027-11-01 · NCT06200181 · CT.gov ↗
What to watch
December 2027 (2)
Early phase / not applicableCoronary Artery Disease, Aortic Valve DiseaseRecruiting
Est. primary completion 2027-12 · NCT05635227 · CT.gov ↗
What to watch
Phase 3Nausea, VomitingRecruiting
Est. primary completion 2027-12-30 · NCT07208305 · CT.gov ↗
What to watch
2028 (3)
April 2028 (1)
Early phase / not applicableLung CancerNot yet recruiting
Est. primary completion 2028-04-30 · NCT07442890 · CT.gov ↗
What to watch
October 2028 (1)
Phase 2Cancer, Advanced Solid Tumors, MalnutritionNot yet recruiting
Est. primary completion 2028-10 · NCT07722806 · CT.gov ↗
What to watch
November 2028 (1)
Phase 2Gastric Adenocarcinoma, Gastric CancerRecruiting
Est. primary completion 2028-11 · NCT07581405 · CT.gov ↗
What to watch
2030 (1)
November 2030 (1)
Phase 2Cancer-Associated Anorexia, Head and Neck Squamous Cell Carcinoma, Neck Squamous Cell Carcinoma of Unknown PrimaryRecruiting
Est. primary completion 2030-11-15 · NCT06995508 · CT.gov ↗
What to watch
2032 (1)
February 2032 (1)
Phase 2SchizophreniaNot yet recruiting
Est. primary completion 2032-02-01 · NCT07152184 · CT.gov ↗
What to watch

See the full readout calendar ↗